Evidence map›Paper›PMID 42878165›Full record

Observational studyClinical transplantation2026

Long-Term Proton Pump Inhibitors in Lung Transplant Recipients: Near-Universal Use Without Clear Impact on Clinical Outcomes Over a 20-Year Observational Study.

Chen Yang Kevin Zhang, Rayoun Ramendra, Meghan Aversa, Rasheed Ghany, Jussi Tikkanen, Ella Huszti, Jonathan Yeung, Shaf Keshavjee, Lianne G Singer, Tereza Martinu

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chen Yang Kevin ZhangToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
Rayoun RamendraToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
Meghan AversaToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
Rasheed GhanyToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
Jussi TikkanenToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
Ella HusztiBiostatistics Research Unit, University Health Network, Toronto, Canada.
Jonathan YeungToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
Shaf KeshavjeeToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
Lianne G SingerToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.
Tereza MartinuToronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, Canada.

Funding

University Health Network Foundation
6 · The paper itself

Abstract

backgroundGastroesophageal reflux disease (GERD) is a known risk factor for chronic lung allograft dysfunction (CLAD), the main barrier to long-term survival in lung transplant recipients (LTR). While proton pump inhibitors (PPI) are effective for symptomatic treatment of GERD, data are sparse on the prevalence of long-term PPI use and association with clinical outcomes.

methodsSingle-center retrospective cohort of adult first-time LTR between 1999 to 2018 who were alive and CLAD-free at 1-year post-transplant. PPI exposure was defined as ≥8 continuous weeks in the first year, started within 6 months post-transplant.

results1308 LTR were included, with 1170 (89.4%) exposed to PPI. PPI use increased over time and remained above 90% from 2007 onwards. In multivariable analyses, LTR on PPI had similar time to CLAD and time to death/retransplant compared to those not on PPI. Similarly, no differences in outcomes were observed between LTR on once-daily and twice-daily dosing, or after accounting for the number of reflux episodes on 24 h pH-impedance monitoring. Positive bronchoalveolar lavage cultures and acute rejection over the first-year post-transplant was also comparable.

conclusionsLong-term use of PPI became near-universal without observable effect on clinical outcomes. While further research is needed, these findings question the routine use of PPI in LTR.

Indexed as

Gastroesophageal RefluxGraft RejectionGraft SurvivalLung TransplantationPostoperative ComplicationsPrimary Graft DysfunctionProton Pump InhibitorsAdultFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsProton Pump Inhibitorschronic lung allograft dysfunctiongastroesophageal refluxlung transplantationobservational studyproton pump inhibitors

Identifiers

PMID42878165
PMCPMC13670396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.